ClinicalTrials.gg
RecruitingNCT05979896Updated Aug 7, 2023

Chemoprevention Efficacy Study Nigeria

A Phase 4 interventional study of Standard age based SPAQ administration for SMC in Malaria, sponsored by Malaria Consortium. Recruiting at 1 site in Nigeria. Open to participants aged 3 Months to 59 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-07.

Sponsored by Malaria Consortium · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2023, 3 years 2 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
800
Allocation
Not applicable
Ages
3 Months to 59 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Malaria by Malaria Consortium — 3 open to participants now, 9 under way, 2 of them phase 3. Malaria · Malaria Consortium.

Started
2023
with 3 others
Phase 4
4 of 10
1 open now
Registered
7th of 10
by date

Among the 10 studies in Malaria by Malaria Consortium, this one is one of 4 that started in 2023, is one of 4 in phase 4, and was the 7th registered.

Malaria

1,186 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

3 of the 10 studies in Malaria by Malaria Consortium are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.

This study: 3 Months to 59 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Malaria by Malaria Consortium, or all of them as a file.
02

Study summary

The study aims to assess the chemoprevention efficacy of Sulfadoxine-Pyrimethamine and Amodiaquine (SPAQ) used in standard age-based dosing regimens used in Seasonal Malaria Chemoprevention (SMC) and SPAQ resistance marker prevalences and assocations among children 3 - 59 months in Sokoto and Kwara States, Nigeria.

Read the detailed description

The study aims (1) to determine the chemoprevention efficacy of Sulfadoxine-Pyrimethamine and Amodiaquine (SPAQ) used in standard age-based dosing regimens for Seasonal Malaria Chemoprevention (SMC) in children 3-59 months and (2) determine the prevalences and associations of drug resistance genotypes associated with resistance to SPAQ.

  1. a prospective cohort study to determine the chemoprevention efficacy of SPAQ (if SPAQ provides 28 days of protection from Plasmodium falciparum (P. falciparum) malaria infection by clearing existing and preventing new infections) and whether drug concentrations and/or resistance influence the ability to clear and prevent these P. falciparum infections.
  2. a resistance markers study in symptomatic RDT positive children 3-59 months to measure sulfadoxine-pyrimethamine and amodiaquine resistance marker prevalence and association.
03

Conditions studied

  • Malaria

Browse trials for

Keywords

  • Seasonal Malaria Chemoprevention
  • Chemoprevention efficacy
  • Antimalarial drug resistance
04

Who can participate

Ages eligible
3 Months to 59 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children between 3-59 months.
  • Being resident in the research study area.
  • Afebrile children with no other malaria associated symptoms in the past 48 hours or at time of recruitment.
  • Consent to participate in the study obtained.
  • Can comply with 3 days DOT of standard SPAQ regimen.
  • Willingness and ability of the child's guardians to comply with the study protocol for the duration of the study including all dry blood spot and slide collections.

Exclusion criteria

Exclusion criteria

  • Symptoms of malaria (tympanic fever ≥ 37.5 °C or history of fever in past 48 hours)
  • Known allergy to SPAQ.
  • Receiving a sulfa-based medication for treatment or prophylaxis, including co-trimoxazole (trimethoprim-sulfamethoxazole).
  • Individuals receiving azithromycin due to the antimalarial activity of azithromycin.
  • Severe malnutrition according to WHO guidelines
  • positive or ARV use (SPAQ MUST NEVER be used with children taking the antiretroviral efavirenz)
  • Chronic illness of any kind.
  • Treatment with an ACT in previous 2 weeks.
  • Previous treatment with SPAQ this malaria season.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    Sulfadoxine-Pyrimethamine + Amodiaquine (SPAQ)

    Children aged 3-59 months will receive directly observed therapy of standard aged based dosing of Sulfadoxine-Pyrimethamine + Amodiaquine (SPAQ) over 3 days.

    Drug: Standard age based SPAQ administration for SMC

Interventions

  • DrugStandard age based SPAQ administration for SMC

    Sulfadoxine-pyrimethamine and amodiaquine (SPAQ) is administered in standard WHO approved age based regimens as used in Seasonal Malaria Chemoprevention Programmes. Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly. Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug. AQ Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine. It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine.

06

What researchers measure

Primary outcomes

  1. Chemoprevention failure as defined by qPCR positive parasites or malaria slide positive parasites

    Malaria slides and dry blood spots (DBS) taken at days 0,7,14, 21, 28 of a one month drug administration cycle will be analysed to detect parasitemia in children treated with SPAQ. Chemoprevention failure has occured if a malaria slide is positive for parasites 7 days or more after drug administration or if a qPCR detects low level parasitemia at the end of the administration cycle (one month).

    Time frame: 28 days

  2. Prevalence of antimalarial resistance markers among chemoprevention failures (as defined in outcome 1)

    All Dried blood spots (DBS) will be analysed for malaria mutation genotypes (dhfr, dhps, Pfcrt, pfmdr1) on baseline and endline and additionally throughout the cycle if a chemoprevention failure (as defined in outcome 1) has occured.

    Time frame: 28 days

  3. Drug concentrations of Sulfadoxine-pyrimethamine and amodiaquine among chemoprevention failures (as defined in outcome 1)

    Drug concentrations of SPAQ will be analyzed on all samples (taken at days 7,14,21,28 throughout the one month cycle) in order to be linked to chemoprevention failures as defined in outcome 1.

    Time frame: 28 days

  4. Prevalence over time of parasites with dhfr/dhps/pfcrt/pfmdr1 mutations in symptomatic children with a positive diagnostic test residing in districts where SMC is implemented

    The outcome measure to meet the secondary objective is the prevalence of molecular markers associated with SP (codons 108, 51 and 59 in dhfr and 437, 540 and 581 in dhps) and amodiaquine (codons 72-76 Pfcrt and 86, 184 and 1246 pfmdr1), as well as other markers of parasite genetic diversity, in blood samples collected from symptomatic children under five years with a positive RDT attending selected health facilities in areas with SMC

    Time frame: 28 days preceding implementation of chemoprevention efficacy study component

07

Study locations

1 of 1 sites recruiting
  • Kwara Sentinell Site
    Kwara, Nigeria
    Recruiting
    • Mohammed Abdulkadir · Contact
    • · Contactdocmohng@gmail.com · +2348065754333
    • Mohammed Abdulkadir, Dr · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Sep 2023, 1 month after the start.

Of 49 non-industry phase 4 interventional studies under Malaria, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 1 month is below that.

Counting every sponsor, half of 50 studies reached it within 18 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2023
First posted
Aug 7, 2023
StartActual
Jul 28, 2023
Primary completionEst.
Sep 15, 2023
CompletionEst.
May 15, 2024
Last update
Aug 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05979896
Lead sponsor
Malaria Consortium
Responsible party
Sponsor
First posted
Aug 7, 2023
Start date
Jul 28, 2023
Primary completion
Sep 15, 2023 (estimated)
Completion
May 15, 2024 (estimated)
Last update
Aug 7, 2023

Study contacts

Craig Bonnington
Contact
C.BONNINGTON@MALARIACONSORTIUM.ORG
+447597549279
Craig Bonnington
principal investigator · Malaria Consortium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion